Dr Stephanie Hanna

PhD, FHEA

2024

• Hanna, S. J. et al. 2024. The type 1 diabetes T cell receptor and B cell receptor repository in the AIRR Data Commons: a practical guide for access, use and contributions through the Type 1 Diabetes AIRR Consortium.. Diabetologia (10.1007/s00125-024-06298-y)
• Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30, pp. 2657-2666. (10.1038/s41591-024-03115-2)

2023

• Taylor, P. et al. 2023. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: Extended follow-up from the CIRTED trial. The Journal of Clinical Endocrinology & Metabolism 108(10), pp. 2615-2625. (10.1210/clinem/dgad084)
• Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14, article number: 1276255. (10.3389/fimmu.2023.1276255)

2022

• Boldison, J. et al. 2022. Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes. Diabetologia 65, article number: 343–355. (10.1007/s00125-021-05595-0)

2021

• Hanna, S. J., Tatovic, D., Thayer, T. C. and Dayan, C. M. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12, article number: 751701. (10.3389/fimmu.2021.751701)
• Thayer, T. C., Davies, J., Pearson, J. A., Hanna, S. J., Wen, L. and Wong, F. S. 2021. Differentiating MHC-dependent and -independent mechanisms of lymph node stromal cell regulation of Proinsulin-specific CD8+ T-Cells in type 1 diabetes. Diabetes 70(2), pp. 529-537., article number: db191050. (10.2337/db19-1050)
• Codd, A. S. et al. 2021. Neutrophilia, lymphopenia and myeloid dysfunction: A living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology 2(1), article number: iqab016. (10.1093/oxfimm/iqab016)
• Hanna, S. J. et al. 2021. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology 2(1) (10.1093/oxfimm/iqaa007)
• Scourfield, D. O. et al. 2021. The role and uses of antibodies in COVID-19 infections: a living review. Oxford Open Immunology 2(1), article number: iqab003. (10.1093/oxfimm/iqab003)

2020

• Hanna, S. J. et al. 2020. Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 63, pp. 1174-1185., article number: Diabetologia volume 63, pages1174–1185(2020). (10.1007/s00125-020-05114-7)
• Arikat, F. et al. 2020. Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes. Journal of Controlled Release 322, pp. 593-601. (10.1016/j.jconrel.2020.02.031)

2019

• Powell, W. et al. 2019. Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot. Journal of Immunological Methods 471, pp. 61-65. (10.1016/j.jim.2019.05.007)

2018

• Powell, W. E. et al. 2018. Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes. Diabetologia 61, pp. 1794-1803. (10.1007/s00125-018-4651-x)

2017

• Zhao, X., Coulman, S. A., Hanna, S. J., Wong, F. S., Dayan, C. M. and Birchall, J. C. 2017. Formulation of hydrophobic peptides for skin delivery via coated microneedles. Journal of Controlled Release 265, pp. 2-13. (10.1016/j.jconrel.2017.03.015)

2016

• Thayer, T. C. et al. 2016. Peripheral proinsulin expression controls low-avidity proinsulin-reactive CD8 T Cells in type 1 diabetes. Diabetes 65(11), pp. 3429-3439. (10.2337/db15-1649)
• Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223, pp. 178-187. (10.1016/j.jconrel.2015.12.040)

2015

• Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146(3), pp. 411-422. (10.1111/imm.12518)

2012

• Harris, S. J. et al. 2012. Genetic ablation of PI3K? results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. European Journal of Immunology 42(12), pp. 3394-3404. (10.1002/eji.201242463)
• Alhadj Ali, M., Hanna, S., Wong, S. and Dayan, C. 2012. Functional modulation of epidermal dendritic cells by topical steroid treatment to optimise the tolerogenic potential of immunotherapy for type 1 diabetes [Abstract]. Diabetologia 55(S1), pp. S192. (10.1007/s00125-012-2688-9)

2011

• Harris, S. J. et al. 2011. Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility.. Journal of Immunology 186(8), pp. 4936-4945. (10.4049/jimmunol.1002350)

2010

• Parry, R. V., Harris, S. J. and Ward, S. G. 2010. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1.. Biochimica et Biophysica Acta 1804(3), pp. 529-597. (10.1016/j.bbapap.2009.09.019)

2009

• Harris, S. 2009. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Current Opinion in Investigational Drugs 10(11), pp. 1151-1162.

2008

• Harris, S., Parry, R., Westwick, J. and Ward, S. 2008. Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. Journal of Biological Chemistry 283, pp. 2465-2469. (10.1074/jbc.r700044200)